MIRM
NASDAQ · Biotechnology
Mirum Pharmaceuticals Inc
$94.01
-2.96 (-3.05%)
Financial Highlights (FY 2026)
Revenue
669.09M
Net Income
-29,984,803
Gross Margin
80.8%
Profit Margin
-4.5%
Rev Growth
+89.1%
D/E Ratio
0.98
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 80.8% | 80.8% | 65.4% | 65.4% |
| Operating Margin | -4.2% | -3.8% | 26.6% | 31.3% |
| Profit Margin | -4.5% | -4.3% | 26.9% | 20.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 669.09M | 353.77M | 354.29M | 334.25M |
| Gross Profit | 540.43M | 285.74M | 231.78M | 218.67M |
| Operating Income | -28,436,388 | -13,531,829 | 94.37M | 104.51M |
| Net Income | -29,984,803 | -14,268,663 | 95.30M | 67.28M |
| Gross Margin | 80.8% | 80.8% | 65.4% | 65.4% |
| Operating Margin | -4.2% | -3.8% | 26.6% | 31.3% |
| Profit Margin | -4.5% | -4.3% | 26.9% | 20.1% |
| Rev Growth | +89.1% | +89.1% | +17.5% | +16.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.36B | 1.36B | 2.46B | 2.09B |
| Total Equity | 1.38B | 1.38B | 3.47B | 3.85B |
| D/E Ratio | 0.98 | 0.98 | 0.71 | 0.54 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 2.71M | 1.36M | 155.69M | 150.12M |
| Free Cash Flow | — | — | 58.63M | 55.44M |